Cynata Therapeutics (ASX:CYP)
We spoke to Dr. Kilian Kelly, CEO of Cynata Therapeutics (ASX:CYP) about the three clinical studies currently ongoing that will read out data in the coming months, the earlier clinical data which has already pointed to efficacy, and the competitive advantage which its stem cells have over competing products.
Looking for the Best ASX Life Sciences stocks to invest in right now?
